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To the Editor: We read with great interest the article by
Rabbani et al. [1], in which the authors present the results
of the first randomised double-blind placebo-controlled trial
of high-dose thiamine for the treatment of microalbumin-
uria in patients with type 2 diabetes. Rabbani et al.
concluded that treatment with thiamine for 3 months
resulted in regression of albuminuria. This is a very
important finding, possibly leading to the further conclu-
sion that high-dose thiamine should be considered as a
novel treatment modality for diabetic nephropathy.
However, there are several issues in the current study
that cause concern. According to the data presented in
Table 1 of the paper, urinary albumin excretion (UAE) in
the intervention group decreased from a median of 43.7 mg/
24 h at baseline to 30.1 mg/24 h after 3 months of treatment
(a difference of –13.6 mg/24 h). In the placebo group, the
corresponding values were 50.9 mg/24 h and 35.5 mg/24 h
(a difference of –15.4 mg/24 h). Changes in UAE are also
presented in Fig. 1a, with values of about –17 mg/24 h for
the intervention group and about –5 mg/24 h for the
placebo group. Since both outcomes represent the same
data, some clarification would be appropriate. The further
decrease in UAE during the washout period in both groups
causes additional concern, as it suggests that factors other
than thiamine may have contributed to the decrease in
UAE.
The authors conclude that thiamine is superior to
placebo because of the difference between the median
values of UAE after 3 months of therapy. However, in order
to validate this conclusion, some further questions need to
be addressed. Although there was no significant difference
between the two groups in median UAE at baseline, this
does not necessarily mean that there was no impact on the
results [2]. In studies with small sample sizes, imbalances
between the two groups can easily occur despite random-
isation. It would also be relevant to know whether there
were any differences in the use of angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers be-
tween the groups and, if they were used, when the
treatments were started. It should be noted that the effects
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Furthermore, the authors mention linear regression of
UAE in relation to treatment time. From the information
presented in the article, we cannot discern, however,
whether the presented rates of decrease in UAE over time
are mean regression coefficients, and in what time unit they
are expressed and whether they differed significantly
between the groups.
Finally, it should be pointed out that less than half of the
group of patients with micro-albuminuria was on anti-
hypertensive treatment, whereas current guidelines prompt
the use of renin–angiotensin–aldosterone system (RAAS)
blockade in all such patients: it is important to know
whether the alleged anti-albuminuric effect occurred in
addition to RAAS blockade.
Therefore, the current data—correctly denoted ‘pilot-
scale’ by the authors—raise interest in a possible renopro-
tective effect of thiamine, but require support from further
studies.
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